[1] A. Villanueva, Hepatocellular Carcinoma, The New England journal of medicine, 380 (2019) 1450-1462.
[2] F. Bray, J. Ferlay, I. Soerjomataram, R.L. Siegel, L.A. Torre, A. Jemal, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA: a cancer journal for clinicians, 68 (2018) 394-424.
[3] L. Kulik, H.B. El-Serag, Epidemiology and Management of Hepatocellular Carcinoma, Gastroenterology, 156 (2019) 477-491 e471.
[4] J. Jarroux, A. Morillon, M. Pinskaya, History, Discovery, and Classification of lncRNAs, Advances in experimental medicine and biology, 1008 (2017) 1-46.
[5] S.U. Schmitz, P. Grote, B.G. Herrmann, Mechanisms of long noncoding RNA function in development and disease, Cellular and molecular life sciences : CMLS, 73 (2016) 2491-2509.
[6] Z. Liu, Y. Wang, L. Wang, B. Yao, L. Sun, R. Liu, T. Chen, Y. Niu, K. Tu, Q. Liu, Long non-coding RNA AGAP2-AS1, functioning as a competitive endogenous RNA, upregulates ANXA11 expression by sponging miR-16-5p and promotes proliferation and metastasis in hepatocellular carcinoma, Journal of experimental & clinical cancer research : CR, 38 (2019) 194.
[7] L. Sun, L. Wang, T. Chen, Y. Shi, B. Yao, Z. Liu, Y. Wang, Q. Li, R. Liu, Y. Niu, K. Tu, Q. Liu, LncRNA RUNX1-IT1 which is downregulated by hypoxia-driven histone deacetylase 3 represses proliferation and cancer stem-like properties in hepatocellular carcinoma cells, Cell death & disease, 11 (2020) 95.
[8] S. Han, D. Cao, J. Sha, X. Zhu, D. Chen, LncRNA ZFPM2-AS1 promotes lung adenocarcinoma progression by interacting with UPF1 to destabilize ZFPM2, Molecular oncology, 14 (2020) 1074-1088.
[9] J. Dai, R. Wei, P. Zhang, P. Liu, Long Noncoding RNA ZFPM2-AS1 Enhances the Malignancy of Cervical Cancer by Functioning as a Molecular Sponge of microRNA-511-3p and Consequently Increasing FGFR2 Expression, Cancer management and research, 12 (2020) 567-580.
[10] G. Sun, C. Wu, ZFPM2-AS1 facilitates cell growth in esophageal squamous cell carcinoma via up-regulating TRAF4, Bioscience reports, 40 (2020).
[11] J.G. Liu, H.B. Wang, G. Wan, M.Z. Yang, X.J. Jiang, J.Y. Yang, Long noncoding RNA ZFPM2-AS1 promotes the tumorigenesis of renal cell cancer via targeting miR-137, European review for medical and pharmacological sciences, 23 (2019) 5675-5681.
[12] Z. Liu, Y. Wang, C. Dou, L. Sun, Q. Li, L. Wang, Q. Xu, W. Yang, Q. Liu, K. Tu, MicroRNA-1468 promotes tumor progression by activating PPAR-gamma-mediated AKT signaling in human hepatocellular carcinoma, Journal of experimental & clinical cancer research : CR, 37 (2018) 49.
[13] L. Wang, L. Sun, Y. Wang, B. Yao, R. Liu, T. Chen, K. Tu, Q. Liu, Z. Liu, miR-1204 promotes hepatocellular carcinoma progression through activating MAPK and c-Jun/AP1 signaling by targeting ZNF418, International journal of biological sciences, 15 (2019) 1514-1522.
[14] L. Sun, L. Wang, T. Chen, B. Yao, Y. Wang, Q. Li, W. Yang, Z. Liu, microRNA-1914, which is regulated by lncRNA DUXAP10, inhibits cell proliferation by targeting the GPR39-mediated PI3K/AKT/mTOR pathway in HCC, Journal of cellular and molecular medicine, 23 (2019) 8292-8304.
[15] Z. Liu, Y. Wang, C. Dou, M. Xu, L. Sun, L. Wang, B. Yao, Q. Li, W. Yang, K. Tu, Q. Liu, Hypoxia-induced up-regulation of VASP promotes invasiveness and metastasis of hepatocellular carcinoma, Theranostics, 8 (2018) 4649-4663.
[16] N. Yang, T. Chen, L. Wang, R. Liu, Y. Niu, L. Sun, B. Yao, Y. Wang, W. Yang, Q. Liu, K. Tu, Z. Liu, CXCR4 mediates matrix stiffness-induced downregulation of UBTD1 driving hepatocellular carcinoma progression via YAP signaling pathway, Theranostics, 10 (2020) 5790-5801.
[17] B. Yao, Y. Li, L. Wang, T. Chen, Y. Niu, Q. Liu, Z. Liu, MicroRNA-3194-3p inhibits metastasis and epithelial-mesenchymal transition of hepatocellular carcinoma by decreasing Wnt/beta-catenin signaling through targeting BCL9, Artificial cells, nanomedicine, and biotechnology, 47 (2019) 3885-3895.
[18] Y. Wang, L. Yang, T. Chen, X. Liu, Y. Guo, Q. Zhu, X. Tong, W. Yang, Q. Xu, D. Huang, K. Tu, A novel lncRNA MCM3AP-AS1 promotes the growth of hepatocellular carcinoma by targeting miR-194-5p/FOXA1 axis, Molecular cancer, 18 (2019) 28.
[19] R. Abdollahzadeh, A. Daraei, Y. Mansoori, M. Sepahvand, M.M. Amoli, J. Tavakkoly-Bazzaz, Competing endogenous RNA (ceRNA) cross talk and language in ceRNA regulatory networks: A new look at hallmarks of breast cancer, Journal of cellular physiology, 234 (2019) 10080-10100.
[20] R. Zhao, S. Du, Y. Liu, C. Lv, Y. Song, X. Chen, B. Zhang, D. Li, S. Gao, W. Cui, M.V. Plikus, X. Hou, K. Wu, Z. Liu, Z. Liu, Y. Cong, Y. Li, Z. Yu, Mucoadhesive-to-penetrating controllable peptosomes-in-microspheres co-loaded with anti-miR-31 oligonucleotide and Curcumin for targeted colorectal cancer therapy, Theranostics, 10 (2020) 3594-3611.
[21] Y.H. Lee, N.Y. Song, J. Suh, D.H. Kim, W. Kim, J. Ann, J. Lee, J.H. Baek, H.K. Na, Y.J. Surh, Curcumin suppresses oncogenicity of human colon cancer cells by covalently modifying the cysteine 67 residue of SIRT1, Cancer letters, 431 (2018) 219-229.
[22] A. Eshaghian, A. Khodarahmi, F. Safari, F. Binesh, A. Moradi, Curcumin attenuates hepatic fibrosis and insulin resistance induced by bile duct ligation in rats, The British journal of nutrition, 120 (2018) 393-403.
[23] X. Chen, F.R. Tang, F. Arfuso, W.Q. Cai, Z. Ma, J. Yang, G. Sethi, The Emerging Role of Long Non-Coding RNAs in the Metastasis of Hepatocellular Carcinoma, Biomolecules, 10 (2019).
[24] F. Kong, X. Deng, X. Kong, Y. Du, L. Li, H. Zhu, Y. Wang, D. Xie, S. Guha, Z. Li, M. Guan, K. Xie, Correction: ZFPM2-AS1, a novel lncRNA, attenuates the p53 pathway and promotes gastric carcinogenesis by stabilizing MIF, Oncogene, 37 (2018) 6010.
[25] J. Li, J. Ge, Y. Yang, B. Liu, M. Zheng, R. Shi, Long noncoding RNA ZFPM2-AS1 is involved in lung adenocarcinoma via miR-511-3p/AFF4 pathway, Journal of cellular biochemistry, 121 (2020) 2534-2542.
[26] M. Xue, W. Tao, S. Yu, Z. Yan, Q. Peng, F. Jiang, X. Gao, lncRNA ZFPM2-AS1 promotes proliferation via miR-18b-5p/VMA21 axis in lung adenocarcinoma, Journal of cellular biochemistry, 121 (2020) 313-321.
[27] Y. Fang, M.J. Fullwood, Roles, Functions, and Mechanisms of Long Non-coding RNAs in Cancer, Genomics, proteomics & bioinformatics, 14 (2016) 42-54.
[28] K.C. Wang, H.Y. Chang, Molecular mechanisms of long noncoding RNAs, Molecular cell, 43 (2011) 904-914.
[29] A.P. Huovila, A.J. Turner, M. Pelto-Huikko, I. Karkkainen, R.M. Ortiz, Shedding light on ADAM metalloproteinases, Trends in biochemical sciences, 30 (2005) 413-422.
[30] J. Mattern, C.S. Roghi, M. Hurtz, V. Knauper, D.R. Edwards, Z. Poghosyan, ADAM15 mediates upregulation of Claudin-1 expression in breast cancer cells, Scientific reports, 9 (2019) 12540.
[31] C. Ungerer, K. Doberstein, C. Burger, K. Hardt, W.H. Boehncke, B. Bohm, J. Pfeilschifter, R. Dummer, D. Mihic-Probst, P. Gutwein, ADAM15 expression is downregulated in melanoma metastasis compared to primary melanoma, Biochemical and biophysical research communications, 401 (2010) 363-369.
[32] B. Ren, S. Luo, X. Tian, Z. Jiang, G. Zou, F. Xu, T. Yin, Y. Huang, J. Liu, Curcumin inhibits liver cancer by inhibiting DAMP molecule HSP70 and TLR4 signaling, Oncology reports, 40 (2018) 895-901.
[33] T. Feng, Y. Wei, R.J. Lee, L. Zhao, Liposomal curcumin and its application in cancer, International journal of nanomedicine, 12 (2017) 6027-6044.